The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Lenalidomide’s place in the myeloma treatment landscape
Lenalidomide is an immunomodulatory drug (IMiD) used for the treatment of myeloma and is known to provide significant clinical benefits to patients. In this video, Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, briefly discusses lenalidomide’s place in the myeloma treatment armamentarium, highlighting its use in triplet and quadruplet combinations. Dr Neri also discusses the benefit of using lenalidomide for maintenance therapy, and the potential benefit of using other CELMoDs and IMiDs for the treatment of myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
